4basebio inks development deal with Heqet Therapeutics

Life sciences company 4basebio announced a joint development agreement with Heqet Therapeutics on Wednesday.

  • 4basebio
  • 28 March 2024 17:21:12
4basebio

Source: Sharecast

The AIM-traded firm said the agreement would be focussed on the development of a non-viral vector, incorporating a proprietary Heqet payload for cardiomyocyte regeneration, and the treatment of myocardial infarction more broadly.

Heqet recently closed an €8m (£6.74m) financing round to progress its development programmes.

It was using its proprietary intellectual property to develop therapies enabling heart regeneration and renewal, thus avoiding scar formation on the heart after a myocardial infarction.

Such scarring could eventually lead to cardiac dysfunction and failure, despite improvements in medical interventions.

Under the agreement, the two companies would evaluate the use of 4basebio’s ‘Hermes’ non-viral nanoparticle for the delivery of payloads targeting cardiomyocyte regeneration.

The successful outcome of the project could lead to the proof-of-concept development of a therapy enabling heart regeneration post infarction.

“We are delighted to be working with Heqet on this novel therapy approach for heart repair following myocardial infarction,” said chief executive and chief scientific officer Dr Heikki Lanckriet.

“This further demonstrates the flexible application of our Hermes targeted delivery technology within the cell and gene therapy markets.”

N/A

Isin: N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes

Compare our accounts

Whether you're looking for a Share Dealing Account or Share Dealing ISA, we've got an account to suit your needs.

Lloyds Bank is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.

Important legal information

The Lloyds Bank Direct Investments Service is operated by Halifax Share Dealing Limited. Registered Office: Trinity Road, Halifax, West Yorkshire, HX1 2RG. Registered in England and Wales no. 3195646. Halifax Share Dealing Limited is authorised and regulated by the Financial Conduct Authority, 12 Endeavour Square, London, E20 1JN under registration number 183332. A Member of the London Stock Exchange and an HM Revenue & Customs Approved ISA Manager.

Logo Allfunds

The information contained within this website is provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd unless otherwise stated. The information is not intended to be advice or a recommendation to buy, sell or hold any of the shares, companies or investment vehicles mentioned, nor is it information meant to be a research recommendation. This is a solution powered by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd incorporating their prices, data news, charts, fundamentals and investor tools on this site. Terms and conditions apply. Prices and trades are provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd and are delayed by at least 15 minutes.

FE fundinfo Logo

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

Refinitiv Logo

© 2024 Refinitiv, an LSEG business. All rights reserved.